Methofill Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. This inhibition reduces the synthesis of DNA, RNA and proteins, leading to decreased proliferation of immune cells and cancer cells, thereby providing immunosuppressive and antineoplastic effects.

The specific dose of Methofill Pen is determined by the prescribing clinician based on the patient’s condition, disease severity, renal and hepatic function, and other individual factors. Only a qualified health professional should set the dosing regimen.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy. Women of child‑bearing potential should use effective contraception before, during, and after treatment. Limited data exist for breastfeeding, and the drug is generally not recommended while nursing.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Methofill Pen offers a prefilled subcutaneous injection pen, which can improve dosing accuracy and patient convenience compared with traditional vial or oral formulations. The pharmacologic profile of methotrexate remains the same, but the pen may reduce injection‑site discomfort and simplify self‑administration.

Methofill Pen should be stored at 2‑8 °C (refrigerated). Keep the pen in its original packaging, protect it from light, and avoid freezing or shaking the device. Do not use the product if it has been exposed to temperatures outside this range.

Methofill Pen is a prefilled injection pen designed for subcutaneous delivery. The prescriber or trained healthcare professional selects the prescribed dose, cleans the injection site, and depresses the pen to inject the medication into the fatty tissue of the abdomen or thigh.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to bone‑marrow suppression, renal failure, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these complications.

Methofill Pen should not be used by individuals who are pregnant, have uncontrolled liver disease, severe renal impairment, known hypersensitivity to methotrexate, or who are receiving live vaccines. It is also contraindicated in patients with active infections that could be worsened by immunosuppression.